| 39.68 Delayed Data As of Apr 22 |  -0.17 / -0.43%Today’s Change | 36.41 Today|||52-Week Range 42.36 | +3.85% Year-to-Date |
| Previous close | 39.85 |
| Today’s open | 39.79 |
| Day’s range | 39.62 - 39.91 |
| Volume | 1,650,085 |
| Average volume (3 months) | 3,067,620 |
| Market cap | $99.4B |
| Earnings growth (last year) | +143.10% |
| Earnings growth (this year) | -7.47% |
| Earnings growth (next 5 years) | +1.00% |
| Revenue growth (last year) | +5.72% |
| P/E ratio | 21.0 |
| Price/Sales | 2.31 |
| Price/Book | 17.67 |
| Today’s change | Today’s % change | |
|---|---|---|
| AZNAstraZeneca | -0.05 | -0.13% |
| SNYSanofi | +0.04 | +0.10% |
| NVONovo Nordisk | -0.29 | -0.60% |
| ABBVAbbVie | +0.58 | +0.75% |
| Next reporting date | May 1, 2019 |
| EPS forecast (this quarter) | $0.67 |
| Annual revenue (last year) | $41.1B |
| Annual profit (last year) | $4.8B |
| Net profit margin | 11.75% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Emma Walmsley |
Chief Financial Officer & Executive Director Iain James Mackay |
Corporate headquarters Brentford, Greater London |
